NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MILPREM-200 is an oral tablet combining conjugated estrogens with meprobamate, a fixed-dose combination historically used for vasomotor symptoms and anxiety in menopausal women. The product is currently in pre-launch status under NDA review by Bausch Health. Mechanism of action details are not publicly available in current regulatory filings.
Pre-Launch
Pre-launch status indicates early commercial infrastructure building; market entry success depends on regulatory approval timeline and competitive positioning in the estrogen-replacement therapy space.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MILPREM-200 offers exposure to regulatory approval processes, legacy product commercialization, and market access strategy in a competitive women's health space. Career growth is limited by the product's pre-launch status, legacy positioning, and expected rapid generic erosion post-approval.
Brand ManagerRegulatory Affairs Specialist
Worked on MILPREM-200 at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.